107 related articles for article (PubMed ID: 23484395)
21. Measuring serum antibody to human papillomavirus following infection or vaccination.
Frazer IH
Gynecol Oncol; 2010 Jun; 118(1 Suppl):S8-11. PubMed ID: 20494221
[TBL] [Abstract][Full Text] [Related]
22. Human papillomavirus, cancer and vaccination.
Heard I
Curr Opin HIV AIDS; 2011 Jul; 6(4):297-302. PubMed ID: 21519247
[TBL] [Abstract][Full Text] [Related]
23. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries.
Goldie SJ; O'Shea M; Campos NG; Diaz M; Sweet S; Kim SY
Vaccine; 2008 Jul; 26(32):4080-93. PubMed ID: 18550229
[TBL] [Abstract][Full Text] [Related]
24. Quadrivalent HPV vaccine in HIV-1-infected early adolescent girls and boys in Kenya: Month 7 and 12 post vaccine immunogenicity and correlation with immune status.
Mugo NR; Eckert L; Magaret AS; Cheng A; Mwaniki L; Ngure K; Celum C; Baeten JM; Galloway DA; Wamalwa D; Wald A
Vaccine; 2018 Nov; 36(46):7025-7032. PubMed ID: 30297124
[TBL] [Abstract][Full Text] [Related]
25. Human Papillomavirus Antibody Levels and Quadrivalent Vaccine Clinical Effectiveness in Perinatally Human Immunodeficiency Virus-infected and Exposed, Uninfected Youth.
Moscicki AB; Karalius B; Tassiopoulos K; Yao TJ; Jacobson DL; Patel K; Purswani M; Seage GR;
Clin Infect Dis; 2019 Sep; 69(7):1183-1191. PubMed ID: 30927547
[TBL] [Abstract][Full Text] [Related]
26. Response to 2009 pandemic and seasonal influenza vaccines co-administered to HIV-infected and HIV-uninfected former drug users living in a rehabilitation community in Italy.
Pariani E; Boschini A; Amendola A; Poletti R; Anselmi G; Begnini M; Ranghiero A; Cecconi G; Zanetti AR
Vaccine; 2011 Nov; 29(49):9209-13. PubMed ID: 21974995
[TBL] [Abstract][Full Text] [Related]
27. Long-term efficacy of human papillomavirus vaccination.
Ault KA
Gynecol Oncol; 2007 Nov; 107(2 Suppl 1):S27-30. PubMed ID: 17938016
[TBL] [Abstract][Full Text] [Related]
28. HIV viral suppression results in higher antibody responses in HIV-positive women vaccinated with the quadrivalent human papillomavirus vaccine.
Money DM; Moses E; Blitz S; Vandriel SM; Lipsky N; Walmsley SL; Loutfy M; Trottier S; Smaill F; Yudin MH; Klein M; Harris M; Cohen J; Wobeser W; Bitnun A; Lapointe N; Samson L; Brophy J; Karatzios C; Ogilvie G; Coutlée F; Raboud J;
Vaccine; 2016 Sep; 34(40):4799-806. PubMed ID: 27544584
[TBL] [Abstract][Full Text] [Related]
29. Co-administration of human papillomavirus-16/18 AS04-adjuvanted vaccine with hepatitis B vaccine: randomized study in healthy girls.
Schmeink CE; Bekkers RL; Josefsson A; Richardus JH; Berndtsson Blom K; David MP; Dobbelaere K; Descamps D
Vaccine; 2011 Nov; 29(49):9276-83. PubMed ID: 21856349
[TBL] [Abstract][Full Text] [Related]
30. Human papillomavirus, human immunodeficiency virus and immunosuppression.
Denny LA; Franceschi S; de Sanjosé S; Heard I; Moscicki AB; Palefsky J
Vaccine; 2012 Nov; 30 Suppl 5():F168-74. PubMed ID: 23199960
[TBL] [Abstract][Full Text] [Related]
31. Persistence of human papillomavirus infection in HIV-infected and -uninfected adolescent girls: risk factors and differences, by phylogenetic type.
Moscicki AB; Ellenberg JH; Farhat S; Xu J
J Infect Dis; 2004 Jul; 190(1):37-45. PubMed ID: 15195241
[TBL] [Abstract][Full Text] [Related]
32. Clinical perspectives on the role of the human papillomavirus vaccine in the prevention of cancer.
Julius JM; Ramondeta L; Tipton KA; Lal LS; Schneider K; Smith JA
Pharmacotherapy; 2011 Mar; 31(3):280-97. PubMed ID: 21361739
[TBL] [Abstract][Full Text] [Related]
33. Randomized trial: immunogenicity and safety of coadministered human papillomavirus-16/18 AS04-adjuvanted vaccine and combined hepatitis A and B vaccine in girls.
Pedersen C; Breindahl M; Aggarwal N; Berglund J; Oroszlán G; Silfverdal SA; Szüts P; O'Mahony M; David MP; Dobbelaere K; Dubin G; Descamps D
J Adolesc Health; 2012 Jan; 50(1):38-46. PubMed ID: 22188832
[TBL] [Abstract][Full Text] [Related]
34. Reported adverse events in girls aged 13-16 years after vaccination with the human papillomavirus (HPV)-16/18 vaccine in the Netherlands.
van Klooster TM; Kemmeren JM; van der Maas NA; de Melker HE
Vaccine; 2011 Jun; 29(28):4601-7. PubMed ID: 21549785
[TBL] [Abstract][Full Text] [Related]
35. [Vaccination against cervical cancer and diseases caused by Human Papillomavirus].
Bornstein J; Tuma R; Zarfati D; Ophir E
Harefuah; 2007 Oct; 146(10):764-9, 814. PubMed ID: 17990391
[TBL] [Abstract][Full Text] [Related]
36. Post-licensure monitoring of HPV vaccine in the United States.
Markowitz LE; Hariri S; Unger ER; Saraiya M; Datta SD; Dunne EF
Vaccine; 2010 Jul; 28(30):4731-7. PubMed ID: 20188681
[TBL] [Abstract][Full Text] [Related]
37. HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine.
Joura EA; Kjaer SK; Wheeler CM; Sigurdsson K; Iversen OE; Hernandez-Avila M; Perez G; Brown DR; Koutsky LA; Tay EH; García P; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Lehtinen M; Steben M; Bosch X; Dillner J; Kurman RJ; Majewski S; Muñoz N; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan J; Lupinacci LC; Giacoletti KE; Lu S; Vuocolo S; Hesley TM; Haupt RM; Barr E
Vaccine; 2008 Dec; 26(52):6844-51. PubMed ID: 18930097
[TBL] [Abstract][Full Text] [Related]
38. Correlating immunity with protection for HPV infection.
Frazer I
Int J Infect Dis; 2007 Nov; 11 Suppl 2():S10-6. PubMed ID: 18162240
[TBL] [Abstract][Full Text] [Related]
39. Optimization of a protocol for the evaluation of antibody responses to human papillomavirus (HPV) vaccination in low-resource settings.
Donkoh ET; Dassah ET; Owusu-Dabo E
BMC Womens Health; 2022 Jun; 22(1):234. PubMed ID: 35710373
[TBL] [Abstract][Full Text] [Related]
40. Review: current knowledge on the role of HPV antibodies after natural infection and vaccination: implications for monitoring an HPV vaccination programme.
Mollers M; Vossen JM; Scherpenisse M; van der Klis FR; Meijer CJ; de Melker HE
J Med Virol; 2013 Aug; 85(8):1379-85. PubMed ID: 23722396
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
